PRKAA1 and hyperlipidemia: Diabetes, obesity and lipid metabolism disorders were significantly associated with AMPK dysfunction, while AMPK agonist 5-aminoimidazole-4-carbox-amideribonucleoside (AICAR) could reduce serum lipid levels [6] in hyperlipidemia patients.